Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that positive data from the NCX 470 Phase 3 studies were highlighted in 2 podium ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. NCX 470 is a nitric oxide-donating bimatoprost eye drop ...
Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results, including two podium presentations, will be ...
(RTTNews) - Nicox SA announced the results of the Whistler Phase 3b exploratory clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in ...
Please provide your email address to receive an email when new articles are posted on . Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients ...
The Denali phase 3 clinical trial met its primary endpoint of demonstrating non-inferiority of NCX 470 0.1% to latanoprost 0.005% at every time point. NCX 470 demonstrated fast, powerful, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results